Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (882)	3/26/2002 8:49:26 PM
From: SemiBull	Read Replies (1) \| Respond to of 1139

ICOS Scheduled at Banc of America Securities Healthcare Conference BOTHELL, Wash.--(BW HealthWire)--March 26, 2002--ICOS Corporation (Nasdaq:ICOS - news) announced today that Thomas P. St. John, Ph.D., Vice President, Therapeutic Development, will speak at the Banc of America Securities Healthcare Conference, on April 3, 2002, at 1:50 p.m. PST. The conference is being held at the Four Seasons Hotel in Las Vegas, Nevada. A webcast of the presentation will be available in real-time and a replay will be available for 48 hours. The webcast can be accessed on the ICOS website, www.icos.com, Investor section. Additional information on ICOS, including press releases, is also available on the website. ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis, pulmonary arterial hypertension and other cardiovascular diseases, and inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing the Company's opportunities for marketing breakthrough products. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in the Company's latest Annual Report on Form 10-K and its other public filings filed with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Contact: ICOS Corporation Lacy Fitzpatrick, 425/415-2207